Company Valuation: Island Pharmaceuticals Limited

Data adjusted to current consolidation scope
Fiscal Period: June 2023 2024 2025 2026 2027 2028
Capitalization 1 7.721 9.761 33.05 140 - -
Change - 26.43% 238.62% 323.6% - -
Enterprise Value (EV) 1 7.721 8.523 33.05 140.6 121.8 397.6
Change - 10.39% 287.83% 325.42% -13.37% 226.41%
P/E ratio -2.94x -2.43x -6.19x -26.8x -10.1x 0.47x
PBR - 6.42x - - - -
PEG - 1.29x 0.2x 1.2x -0x -0x
Capitalization / Revenue - - - - - 0.28x
EV / Revenue - - - - - 0.8x
EV / EBITDA - -3.02x - -21.6x -6.48x 0.94x
EV / EBIT - -3.02x - -21.6x -6.48x 0.94x
EV / FCF - - - -16.9x -6.48x 1.44x
FCF Yield - - - -5.9% -15.4% 69.4%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -0.0323 -0.0317 -0.0226 -0.0177 -0.047 1.011
Distribution rate - - - - - -
Net sales 1 - - - - - 500
EBITDA 1 - -2.818 - -6.5 -18.8 420.8
EBIT 1 - -2.818 - -6.5 -18.8 420.8
Net income 1 -2.83 -2.864 -3.92 -4.6 -13.2 294.7
Net Debt 1 - -1.238 - 0.6 -18.2 257.6
Reference price 2 0.0950 0.0770 0.1400 0.4750 0.4750 0.4750
Nbr of stocks (in thousands) 81,268 126,767 236,093 294,767 - -
Announcement Date 30/8/23 29/8/24 28/8/25 - - -
1AUD in Million2AUD
Estimates

P/E ratio, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
-27.68x - -22.31x - 103M
42.74x10x36.07x0.03% 44.8B
15.94x5.69x12.52x1.88% 40.35B
-51.84x17.45x-57.65x-.--% 30.05B
-17.5x4.48x-8.41x-.--% 21.8B
27.64x5.7x15.82x-.--% 19.09B
22.04x4.19x13.68x-.--% 16.72B
-329.09x27.33x1504.74x-.--% 13.53B
-14.2x6349.59x-18.15x-.--% 12.47B
-169.65x41.3x-164.02x-.--% 12.1B
Average -50.16x 718.41x 131.23x 0.21% 21.1B
Weighted average by Cap. -24.50x 386.49x 89.45x 0.36%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. ILA Stock
  4. Valuation Island Pharmaceuticals Limited
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW